Wnt signaling is commonly activated in prostate cancer, particularly metastatic prostate cancer, and clinical data has revealed oncogenic Wnt signaling is correlated with a high Gleason score, high prostate specific antigen (PSA) serum levels, early disease onset (<50 years of age), and disease recurrence [15,16,18,19]. Here, KLK3 is linked to prostate cancer.